These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29716594)

  • 1. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.
    Zarzeczny A; Clark M
    BMC Med Ethics; 2014 Oct; 15():75. PubMed ID: 25315976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better?
    Ogbogu U; Rachul C; Caulfield T
    Regen Med; 2013 May; 8(3):361-9. PubMed ID: 23627829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies.
    Murdoch B; Zarzeczny A; Caulfield T
    BMJ Open; 2018 Feb; 8(2):e019414. PubMed ID: 29490963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.
    Master Z; Fu W; Paciulli D; Sipp D
    Clin Pharmacol Ther; 2017 Aug; 102(2):177-179. PubMed ID: 28695633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Academic physician specialists' views toward the unproven stem cell intervention industry: areas of common ground and divergence.
    Smith C; Crowley A; Munsie M; DeMartino ES; Staff NP; Shapiro S; Master Z
    Cytotherapy; 2021 Apr; 23(4):348-356. PubMed ID: 33563545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating the advertising and promotion of stem cell therapies.
    von Tigerstrom B
    Regen Med; 2017 Oct; 12(7):815-826. PubMed ID: 29112482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
    Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
    Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.
    Horner C; Tenenbaum E; Sipp D; Master Z
    NPJ Regen Med; 2018; 3():5. PubMed ID: 29479481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the margins to mainstream: How providers of autologous 'stem cell treatments' legitimise their practice in Australia.
    MacGregor C; Petersen A; Munsie M
    Health (London); 2021 Jan; 25(1):51-68. PubMed ID: 31081381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Professional regulation: a potentially valuable tool in responding to "stem cell tourism".
    Zarzeczny A; Caulfield T; Ogbogu U; Bell P; Crooks VA; Kamenova K; Master Z; Rachul C; Snyder J; Toews M; Zoeller S
    Stem Cell Reports; 2014 Sep; 3(3):379-84. PubMed ID: 25241736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical considerations when counseling patients about stem cell tourism.
    Tsou A
    Continuum (Minneap Minn); 2015 Feb; 21(1 Spinal Cord Disorders):201-5. PubMed ID: 25651226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell tourism and doctors' duties to minors--a view from Canada.
    Zarzeczny A; Caulfield T
    Am J Bioeth; 2010 May; 10(5):3-15. PubMed ID: 20461636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles and responsibilities of physicians in patients' decisions about unproven stem cell therapies.
    Levine AD; Wolf LE
    J Law Med Ethics; 2012; 40(1):122-34. PubMed ID: 22458467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.
    Matthews KRW; Lowe SJ; Master Z
    Cytotherapy; 2024 Apr; 26(4):404-409. PubMed ID: 38310500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell/cellular interventions in human spinal cord injury: Is it time to move from guidelines to regulations and legislations? Literature review and Spinal Cord Society position statement.
    Chhabra HS; Sarda K; Jotwani G; Gourie-Devi M; Kaptanoglu E; Charlifue S; Yadav SL; Mohapatra B; Srivastava A; Phadke K
    Eur Spine J; 2019 Aug; 28(8):1837-1845. PubMed ID: 31098715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Online Direct-to-Consumer Advertising of Stem Cell Therapy for Musculoskeletal Injury and Disease: Misinformation and Violation of Ethical and Legal Advertising Parameters.
    Kingery MT; Schoof L; Strauss EJ; Bosco JA; Halbrecht J
    J Bone Joint Surg Am; 2020 Jan; 102(1):2-9. PubMed ID: 31770294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.